Evidence map›Paper›PMID 32677911›Full record

Trial reportBMC pregnancy and childbirth2020

The WOMAN trial: clinical and contextual factors surrounding the deaths of 483 women following post-partum haemorrhage in developing countries.

Roberto Picetti, Lori Miller, Haleema Shakur-Still, Tracey Pepple, Danielle Beaumont, Eni Balogun, Etienne Asonganyi, Rizwana Chaudhri, Mohamed El-Sheikh, Bellington Vwalika and 3 more

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in BMC pregnancy and childbirth, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
7.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. The cost-effectiveness of tranexamic acid for treatment of postpartum hemorrhage: A systematic review.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2021
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. Neutrophil-to-lymphocyte ratio at admission helps to predict the need for blood transfusion after vaginal delivery.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Peripartum Haemorrhage: Haemostatic Aspects of the Updated Peripartum Haemorrhage Guideline of the German-Speaking Countries.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2023
    Review
  11. Article
  12. Observational
  13. Tranexamic Acid for Postpartum Hemorrhage Treatment in Low-Resource Settings: A Rapid Scoping Review.International journal of environmental research and public health · 2022
    Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 4 countries.

Roberto PicettiClinical Trials Unit, London School of Hygiene & Tropical Medicine, Keppel Street, London, WC1E 7HT, UK. roberto.picetti@lshtm.ac.uk.ORCID http://orcid.org/0000-0003-4756-5271
Lori MillerClinical Trials Unit, London School of Hygiene & Tropical Medicine, Keppel Street, London, WC1E 7HT, UK.
Haleema Shakur-StillClinical Trials Unit, London School of Hygiene & Tropical Medicine, Keppel Street, London, WC1E 7HT, UK.
Tracey PeppleClinical Trials Unit, London School of Hygiene & Tropical Medicine, Keppel Street, London, WC1E 7HT, UK.
Danielle BeaumontClinical Trials Unit, London School of Hygiene & Tropical Medicine, Keppel Street, London, WC1E 7HT, UK.
Eni BalogunClinical Trials Unit, London School of Hygiene & Tropical Medicine, Keppel Street, London, WC1E 7HT, UK.
Etienne AsonganyiMaternity Unit, Kumba District Hospital, Kumba, Southwest Province, Cameroon.
Rizwana ChaudhriHoly Family Hospital, Gynaecology & Obstetrics Unit 1, F-762 Said Pur Road, Satellite Town, Rawalpindi, Pakistan.
Mohamed El-SheikhDepartment of Obstetrics and Gynaecology, Faculty of Medicine, University of Khartoum, Khartoum, Sudan.
Bellington VwalikaDepartment of Obstetrics and Gynaecology, School of Medicine, University of Zambia, Lusaka, Zambia.
Sabaratnam ArulkumaranSt George's University of London, Room 1.126, First Floor, Jenner Wing, Cranmer Terrace, London, SW17 0RE, UK.
Ian RobertsClinical Trials Unit, London School of Hygiene & Tropical Medicine, Keppel Street, London, WC1E 7HT, UK.
WOMAN trial collaborators
University of London · GBHoly Family Hospital · PKSt George's, University of London · GBUniversity of Khartoum · SDUniversity of Zambia · ZM

Funding

Wellcome TrustWellcome Trust WT208870/Z/17/Z
6 · The paper itself

Abstract

backgroundPost-partum haemorrhage (PPH) is a leading cause of maternal death worldwide. The WOMAN trial assessed the effects of tranexamic acid (TXA) on death and surgical morbidity in women with PPH. The trial recorded 483 maternal deaths. We report the circumstances of the women who died.

methodsThe WOMAN trial recruited 20,060 women with a clinical diagnosis of PPH after a vaginal birth or caesarean section. We randomly allocated women to receive TXA or placebo. When a woman died, we asked participating clinicians to report the cause of death and to provide a short narrative of the events surrounding the death. We collated and edited for clarity the narrative data.

resultsCase fatality rates were 3.0% in Africa and 1.7% in Asia. Nearly three quarters of deaths were within 3 h of delivery and 91% of these deaths were from bleeding. Women who delivered outside a participating hospital (12%) were three times more likely to die (OR = 3.12, 95%CI 2.55-3.81) than those who delivered in hospital. Blood was often unavailable due to shortages or because relatives could not afford to buy it. Clinicians highlighted late presentation, maternal anaemia and poor infrastructure as key contributory factors.

conclusionsAlthough TXA use reduces bleeding deaths by almost one third, mortality rates similar to those in high income countries will not be achieved without tackling late presentation, maternal anaemia, availability of blood for transfusion and poor infrastructure.

Indexed as

AdultAfricaAnemiaAntifibrinolytic AgentsAsiaBlood TransfusionCause of DeathCesarean SectionDeveloping CountriesEuropeFemaleHumansMaternal MortalityPostpartum HemorrhagePostpartum PeriodPregnancyAntifibrinolytic AgentsTranexamic Acid

Identifiers

PMID32677911
PMCPMC7364536
OpenAlexW3042385256

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.